A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure

Trial Profile

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Sponsors Zensun (Shanghai) Sci & Tech
  • Most Recent Events

    • 12 Mar 2018 Interim results presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 19 Dec 2017 Status changed from recruiting to discontinued.
    • 07 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top